Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 20 | 2025 | 301 | 4.120 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2025 | 51 | 1.270 |
Why?
|
| HIV Infections | 8 | 2024 | 402 | 1.150 |
Why?
|
| Genital Neoplasms, Female | 6 | 2025 | 48 | 1.030 |
Why?
|
| Botswana | 15 | 2025 | 32 | 0.920 |
Why?
|
| Electrosurgery | 1 | 2025 | 10 | 0.900 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2024 | 332 | 0.820 |
Why?
|
| Gynecology | 3 | 2021 | 52 | 0.790 |
Why?
|
| Obstetrics | 2 | 2020 | 87 | 0.710 |
Why?
|
| Adnexal Diseases | 1 | 2020 | 3 | 0.640 |
Why?
|
| Rwanda | 7 | 2024 | 15 | 0.570 |
Why?
|
| Time-to-Treatment | 3 | 2025 | 81 | 0.570 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 459 | 0.470 |
Why?
|
| Chemoradiotherapy | 3 | 2025 | 50 | 0.460 |
Why?
|
| Radiation Oncology | 2 | 2023 | 26 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1043 | 0.400 |
Why?
|
| Female | 27 | 2025 | 28782 | 0.400 |
Why?
|
| Neoplasm Staging | 6 | 2025 | 774 | 0.390 |
Why?
|
| Hysterectomy | 2 | 2024 | 91 | 0.380 |
Why?
|
| Medical Oncology | 2 | 2025 | 97 | 0.380 |
Why?
|
| Middle Aged | 13 | 2025 | 13419 | 0.330 |
Why?
|
| Palliative Care | 4 | 2024 | 195 | 0.290 |
Why?
|
| Humans | 28 | 2025 | 53230 | 0.290 |
Why?
|
| Adult | 13 | 2025 | 14534 | 0.260 |
Why?
|
| Patient Care Team | 2 | 2025 | 278 | 0.240 |
Why?
|
| Prospective Studies | 7 | 2025 | 2411 | 0.230 |
Why?
|
| Retrospective Studies | 4 | 2025 | 6819 | 0.220 |
Why?
|
| Induction Chemotherapy | 1 | 2025 | 65 | 0.220 |
Why?
|
| Hospitals, Teaching | 1 | 2024 | 52 | 0.210 |
Why?
|
| Early Detection of Cancer | 5 | 2024 | 190 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2024 | 122 | 0.210 |
Why?
|
| Papillomavirus Infections | 2 | 2023 | 177 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 124 | 0.190 |
Why?
|
| Universities | 1 | 2024 | 186 | 0.190 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2021 | 9 | 0.180 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2021 | 19 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2021 | 26 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 647 | 0.170 |
Why?
|
| Vulvar Neoplasms | 1 | 2021 | 61 | 0.170 |
Why?
|
| Education, Distance | 1 | 2021 | 43 | 0.170 |
Why?
|
| Education, Medical, Continuing | 1 | 2021 | 76 | 0.160 |
Why?
|
| International Educational Exchange | 1 | 2019 | 6 | 0.150 |
Why?
|
| Ascites | 1 | 2019 | 31 | 0.150 |
Why?
|
| Organizations | 1 | 2018 | 7 | 0.150 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 47 | 0.150 |
Why?
|
| Government Programs | 1 | 2018 | 16 | 0.150 |
Why?
|
| International Cooperation | 1 | 2018 | 52 | 0.140 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 68 | 0.140 |
Why?
|
| Capacity Building | 1 | 2018 | 26 | 0.140 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 477 | 0.140 |
Why?
|
| Prenatal Care | 1 | 2019 | 111 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 405 | 0.140 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2019 | 151 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2025 | 5595 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 867 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 231 | 0.130 |
Why?
|
| Schools | 1 | 2018 | 185 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1038 | 0.120 |
Why?
|
| Health Personnel | 1 | 2018 | 259 | 0.120 |
Why?
|
| Young Adult | 1 | 2025 | 4511 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2019 | 439 | 0.100 |
Why?
|
| Carboplatin | 2 | 2025 | 57 | 0.100 |
Why?
|
| Aged | 5 | 2025 | 10429 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2025 | 91 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 78 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2014 | 229 | 0.100 |
Why?
|
| Developing Countries | 2 | 2025 | 66 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 2 | 2022 | 121 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 1723 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2024 | 445 | 0.090 |
Why?
|
| Vulnerable Populations | 2 | 2021 | 54 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 487 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2014 | 1368 | 0.080 |
Why?
|
| Pandemics | 2 | 2025 | 595 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 317 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2024 | 1557 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2025 | 51 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2024 | 33 | 0.050 |
Why?
|
| Africa | 1 | 2023 | 13 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 64 | 0.050 |
Why?
|
| Cisplatin | 1 | 2025 | 282 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 774 | 0.050 |
Why?
|
| Pregnancy | 2 | 2019 | 2608 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 73 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 600 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 1136 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1034 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 29 | 0.040 |
Why?
|
| Health Resources | 1 | 2021 | 72 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 92 | 0.040 |
Why?
|
| Coinfection | 1 | 2021 | 41 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 466 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2021 | 179 | 0.040 |
Why?
|
| Geographic Information Systems | 1 | 2019 | 15 | 0.040 |
Why?
|
| Financial Management | 1 | 2018 | 10 | 0.040 |
Why?
|
| Infant, Low Birth Weight | 1 | 2019 | 77 | 0.040 |
Why?
|
| Anxiety | 1 | 2021 | 321 | 0.040 |
Why?
|
| Faculty | 1 | 2018 | 71 | 0.040 |
Why?
|
| Mass Screening | 1 | 2021 | 362 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1212 | 0.030 |
Why?
|
| United States | 2 | 2019 | 5409 | 0.030 |
Why?
|
| Students | 1 | 2018 | 249 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 2318 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 2991 | 0.030 |
Why?
|
| Laparotomy | 1 | 2014 | 37 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 3494 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 2913 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1219 | 0.020 |
Why?
|